



Glomerulonephritis: Pathogenesis, Risk Factors, and Treatment

Guest Editor:

Dr. Giovanni Conti

Pediatric Nephrology Unit, AOU
Policlinic "G Martino", University
of Messina, 98125 Messina, Italy

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues

Glomerulonephritis, one of the leading causes of end-stage renal disease, is a group of rare diseases with different presentations, clinical courses, and outcomes. The main causes of chronic kidney disease are hypertension and diabetes, which mainly affect adulthood. However, there are several chronic glomerulonephritis types or idiopathic or secondary to autoimmune diseases that instead begin in adolescent or juvenile age. Kidney biopsy remains the cornerstone for the evaluation of these glomerular diseases. In recent years, clinical and laboratory research has made significant contributions to the understanding of the pathogenesis of glomerulonephritis that is however still uncertain and not completely understood. Current treatment is based on the use of corticosteroids and immunosuppressive drugs. These drugs, which have improved the course of these chronic glomerulonephritis diseases, are however toxic and have many side effects. Recent pathogenetic knowledge has determined the development of a new therapy, especially biological drugs, with excellent efficacy and few side effects.





medicina



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian
University of Health Sciences,
Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*General Medicine*)

Contact Us

Medicina Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/medicina
medicina@mdpi.com